Skip to content
OpenCapital
Get started

United Therapeutics UTHR Total Tyvaso — Total revenues

Other product segments

Tyvaso DPI
$330.3M+9.2%
Orenitram
$135.6M+12.3%
Nebulized Tyvaso
$127.2M-22.3%
Remodulin
$126.6M-8.4%
Unituxin
$53.6M-7.9%
Adcirca
$2.9M-51.7%

Similar metrics at other companies

Biogen logo
BIIBTYSABRI — Total Revenue
$441.5M+15.7%
Mannkind logo
MNKDCollaborations And Services Related To Tyvaso DPI — Cost Of Revenue
$10M-27.0%
Mannkind logo
MNKDTyvaso DPI — Percentage Of Royalty On Net Sales
10%0.0pp
Organon logo
OGNVytorin — Revenue
$21M-8.7%
Mannkind logo
MNKDTyvaso DPI — Percentage Of Royalty On Net Revenue
10%0.0pp
Gilead Sciences logo
GILDTrodelvy — Total revenues
$402M+37.2%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's total tyvaso — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's total tyvaso — total revenues?
United Therapeutics (UTHR) reported total tyvaso — total revenues of $457.5M in Q1 2026.
How has United Therapeutics's total tyvaso — total revenues changed year-over-year?
United Therapeutics's total tyvaso — total revenues decreased by 1.9% year-over-year, from $466.3M to $457.5M.
What is the long-term trend for United Therapeutics's total tyvaso — total revenues?
Over 4 years (2021 to 2025), United Therapeutics's total tyvaso — total revenues has grown at a 32.6% compound annual growth rate (CAGR), from $607.5M to $1.88B.
What does total tyvaso — total revenues mean?
This metric represents the total gross revenue generated from the sale of an inhaled prostacyclin therapy used to treat pulmonary arterial hypertension. As a primary revenue driver for the company, it reflects market adoption, patient adherence, and the competitive positioning of the product within the specialized PAH therapeutic landscape. Monitoring this figure provides insight into the commercial success of the company's core product line and its ability to maintain market share in the rare disease space.